Search

Dr. Craig Thompson, Dr. Peter Bach, Dr. Ushma Neill, and Dr. William Rosa were recognized for their professional, civic, and philanthropic achievements.

… Monday, July 12, 2021 Memorial Sloan Kettering is proud to announce that President & Chief Executive Officer Craig B. Thompson, MD , Director of the Center for Health Policy and Outcomes Peter B. Bach, MD, Vice President of Scientific Education & Training Ushma Neill, PhD , and Postdoctoral Research

The May 13 installment of “MSK Science Spotlight” will feature co-winner of The Society of Memorial Sloan Kettering Prize, Carl June, MD.

… Wednesday, May 13, 2020 The May 13 installment of “MSK Science Spotlight” will feature co-winner of The Society of Memorial Sloan Kettering Prize, Carl June, MD. Dr. June is Director of the Center for Cellular Immunotherapies and Professor, Department of Pathology and Laboratory Medicine, Perelman School

Learn how proton therapy can be an effective new treatment for leptomeningeal metastasis.

… Monday, June 6, 2022 Leptomeningeal metastasis (LM) is a serious condition in which cancer spreads to the fluid and tissues surrounding the brain and spinal cord. This complication can have devastating effects, causing pain, seizures, difficulty thinking, and a loss of muscle control. Treatment with

In honor of Women's History Month, meet the scientific hero who shook up cancer research with her unusual findings.

… Wednesday, March 13, 2019 Summary In honor of Women’s History Month, we’re remembering female scientists from MSK’s past who shook up cancer research. Read about Ora Rosen and  Mathilde Krim . In the 1950s, the idea that cancer might be caused by a virus was somewhat heretical. Most known viruses caused

In cancer care, firsts make a difference. At MSK, we are constantly improving how we help people with those important firsts. Dr. Selwyn Vickers writes about the latest developments at MSK and the encouraging evidence that we are making progress in our mission of ending cancer for life.

… Saturday, July 1, 2023 Dear MSK Community, In cancer care, firsts make a difference: The first tests that diagnosis the disease. The first choices about where to be treated. The first decisions about how to treat it. At Memorial Sloan Kettering Cancer Center (MSK), we are constantly improving how we

More than 30,000 oncology professionals from around the world will gather in Chicago from May 31 to June 4 for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. For more information and to set up interviews, email [email protected]. Follow the meeting live on Twitter using the hashtag #ASCO19 and follow MSK on Twitter at @sloan_kettering.

… Wednesday, May 29, 2019 More than 30,000 oncology professionals from around the world will gather in Chicago from May 31 to June 4 for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. MSK scientists and physicians will take part in nearly 140 presentations from plenary sessions to

Topical minoxidil can be of significant benefit to women with breast cancer who develop alopecia during treatment with endocrine therapies, our most recent research shows.

… Wednesday, May 16, 2018 Topical minoxidil can be of significant benefit to women with breast cancer who develop alopecia during treatment with endocrine therapies, our most recent research shows. In the study, published in JAMA Dermatology , (1)) we identified alopecia with a similar pattern to the androgenetic

Meet the four young ambassadors featured in the annual Stop & Shop campaign to fundraise for the Department of Pediatrics at Memorial Sloan Kettering.

… Monday, June 11, 2018 Summary For nearly 20 years, Memorial Sloan Kettering has partnered with Stop & Shop supermarkets to raise funds for pediatric cancer research. Meet the four spunky kids representing MSK across New York, New Jersey, and Connecticut for this year’s campaign. The next time you visit

A phase 3 trial for myelofibrosis found that adding pelabresib to ruxolitinib was more effective than ruxolitinib alone and did not significantly increase side effects.

… Tuesday, April 29, 2025 An international phase 3 clinical trial of a new drug combination for treating the blood cancer  myelofibrosis found that adding a second, experimental drug to standard treatment was more effective than the standard treatment alone. Further, adding the second drug did not significantly

New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.

… Thursday, February 27, 2014 New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain. Published in the February 27 issue of Cell , the study found that tumor cells that reach the brain — and successfully